Insider Selling: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells 134,713 Shares of Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Syros Pharmaceuticals Stock Performance

Shares of SYRS traded up $0.02 on Wednesday, reaching $0.27. 4,938,782 shares of the stock traded hands, compared to its average volume of 2,378,885. The firm has a market cap of $7.18 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. Syros Pharmaceuticals, Inc. has a 12 month low of $0.18 and a 12 month high of $8.17. The stock’s 50-day moving average price is $1.79 and its 200-day moving average price is $3.49.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the firm earned ($1.35) EPS. Equities analysts forecast that Syros Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SYRS shares. HC Wainwright restated a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com began coverage on Syros Pharmaceuticals in a research report on Thursday, November 21st. They issued a “sell” rating on the stock. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.33.

Institutional Trading of Syros Pharmaceuticals

Several institutional investors have recently bought and sold shares of SYRS. Opaleye Management Inc. boosted its stake in Syros Pharmaceuticals by 119.1% in the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock valued at $4,213,000 after buying an additional 428,175 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. Vanguard Group Inc. boosted its stake in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after buying an additional 163,234 shares in the last quarter. Certuity LLC acquired a new stake in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares in the last quarter. Institutional investors and hedge funds own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.